Argenx Se (ARGX) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Argenx Se ARGX is currently developing the following drugs: Intravenous Immunoglobulin, Empasiprubart Iv, Efgartigimod Ph20 Sc Via Pfs, Efgartigimod Ph20 Sc Via Ai, Argx-121, Empasiprubart Iv, Efgartigimod Ph20 Sc Pfs, Empasiprubart Iv, Efgartigimod Ph20 Sc, Argx-124, Argx-119 Iv, Efgartigimod Iv, Empasiprubart Iv, Efgartigimod Iv, Argx-213, Ivig, Empasiprubart, Argx-109, Empasiprubart, Ivig, Efgartigimod Ph20 Sc - Prefilled Syringe, Argx-119, Efgartigimod, Efg Ph20 Sc, Argx-117, Efgartigimod Ph20 Sc As A Prefilled Syringe Presentation, Efgartigimod Ph20 Sc As A Vial + Syringe Presentation. These drug candidates are in various stages of clinical development as the company works toward FDA approval.